Cabinet Approves Shutdown of Bibcol Vaccine PSU: End of a Polio-Fighting Era

The term कैबिनेट (Cabinet) has trended in India following a significant decision by the central government to shut down the Bharat Immunologicals and Biologicals Corporation Limited (Bibcol). In a mid-September 2026 meeting chaired by Prime Minister Narendra Modi, the Union Cabinet approved the proposal to close this public sector undertaking (PSU), marking the end of a 37-year journey for the vaccine manufacturer [1].

The Rise and Fall of Bibcol

Established on March 10, 1989, under the Department of Biotechnology, Bibcol was designed to make India self-reliant in vaccine production. Its primary mission was the manufacture of the Oral Polio Vaccine (OPV) for the national immunization program. Based in Chola, Bulandshahr district of Uttar Pradesh, the company played a historic role in India's fight against polio, supplying billions of doses to help the country achieve polio-free status [2].

Beyond polio vaccines, the PSU also produced zinc tablets and diarrhea management kits. However, the company's viability collapsed when its main manufacturing unit ceased the production of OPV at the end of December 2022 [3].

Financial Crisis and Employee Hardship

The cessation of production led to severe financial instability and sustained losses. This economic strain directly impacted the workforce, with reports indicating that employees have not received salaries for approximately two years [1]. While the company once employed around 300 staff during its peak, the workforce had dwindled to approximately 90 officers and employees by September 2026 [2].

Key Timeline of Bibcol's Decline

Year/Date	Event
March 10, 1989	Bibcol established under the Department of Biotechnology.
December 2022	Production of Oral Polio Vaccine (OPV) completely halted.
2024–2026	Period of sustained financial losses and unpaid employee salaries.
September 2026	Union Cabinet approves the proposal to shut down the PSU.

Implications for Public Health Infrastructure

The decision to close Bibcol highlights the challenges facing specialized public sector vaccine units when their primary product becomes obsolete or redundant. While Bibcol's contribution to the polio-eradication effort was immense, the lack of a diversified product pipeline left it vulnerable once OPV production stopped. The shutdown reflects a broader trend of the government consolidating or closing non-viable PSUs that are no longer economically sustainable [3].